Sunho Biologics, Inc. (Sunho Biologics) released a supplemental announcement detailing the due-diligence process and rationale behind appointing an external firm (the “Investigator”) to conduct an independent forensic investigation into previously reported irregularities. Trading in the company’s shares, suspended since 09:00 a.m. on 1 April 2026, will remain halted pending publication of the FY2025 annual results.\n\nKey Points of the Supplemental Announcement\n• Independence: The Investigator confirmed no past or present business ties or shareholding interests with Sunho Biologics, its subsidiaries, directors, chief executive, substantial shareholders or connected persons. It has also had no involvement in any transactions linked to the irregularities under review.\n\n• Investigation Team Profile: An eight-member forensic unit will conduct the work. Leadership rests with a senior partner holding Fellow or member status in HKICPA, ICAEW, TIHK and CPA Australia and registered as a Public Interest Entity Auditor with the Accounting and Financial Reporting Council. \n – A principal partner with roughly 20 years’ audit, compliance and forensic accounting experience will support the engagement. \n – Digital forensics capabilities include a computer forensic expert with GPEN and ISO 27001 certifications and more than two decades in IT security, plus a nationally certified electronic data forensics specialist active since 1991. \n – Two additional forensic advisers add more than 20 years’ combined expertise in internal control, risk management and investigations.\n\n• Resources and Timeline: The Investigator has committed dedicated staffing and a work schedule aligned with the Group’s plan for satisfying the Hong Kong Stock Exchange’s resumption guidance.\n\nGovernance Oversight\nThe Independent Investigation Committee concluded that the Investigator meets all requisite standards of independence, credentials, experience and resource adequacy to carry out the forensic probe.\n\nNext Steps and Trading Status\nShare trading will remain suspended until Sunho Biologics publishes its audited FY2025 results. The company advises shareholders and potential investors to exercise caution when dealing in its securities and seek professional advice where necessary.\n\nBoard Composition (as of 19 August 2026)\nExecutive Directors: Chairman Zhang Feng; Jiang Xiaoling.\nIndependent Non-Executive Directors: Chan Heung Wing Anthony, Feng Lan, Shi Luwen.